Direkt zum Inhalt
Merck
  • Calcineurin inhibitors stimulate and mycophenolic acid inhibits replication of hepatitis E virus.

Calcineurin inhibitors stimulate and mycophenolic acid inhibits replication of hepatitis E virus.

Gastroenterology (2014-03-04)
Yijin Wang, Xinying Zhou, Yannick Debing, Kan Chen, Luc J W Van Der Laan, Johan Neyts, Harry L A Janssen, Herold J Metselaar, Maikel P Peppelenbosch, Qiuwei Pan
ZUSAMMENFASSUNG

Many recipients of organ transplants develop chronic hepatitis, due to infection with the hepatitis E virus (HEV). Although chronic HEV infection is generally associated with immunosuppressive therapies, little is known about how different immunosuppressants affect HEV infection. A subgenomic HEV replication model, in which expression of a luciferase reporter gene is measured, and a full-length infection model were used. We studied the effects of different immunosuppressants, including steroids, calcineurin inhibitors (tacrolimus [FK506] and cyclosporin A), and mycophenolic acid (MPA, an inhibitor of inosine monophosphate dehydrogenase) on HEV replication in human hepatoma cell line Huh7. Expression of cyclophilins A and B (the targets of cyclosporin A) were knocked down using small hairpin RNAs. Steroids had no significant effect on HEV replication. Cyclosporin A promoted replication of HEV in the subgenomic and infectious models. Knockdown of cyclophilin A and B increased levels of HEV genomic RNA by 4.0- ± 0.6-fold and 7.2- ± 1.9-fold, respectively (n = 6; P < .05). A high dose of FK506 promoted infection of liver cells with HEV. In contrast, MPA inhibited HEV replication. Incubation of cells with guanosine blocked the antiviral activity of MPA, indicating that the antiviral effects of this drug involve nucleotide depletion. The combination of MPA and ribavirin had a greater ability to inhibit HEV replication than MPA or ribavirin alone. Cyclophilins A and B inhibit replication of HEV; this might explain the ability of cyclosporin A to promote HEV infection. On the other hand, the immunosuppressant MPA inhibits HEV replication. These findings should be considered when physicians select immunosuppressive therapies for recipients of organ transplants who are infected with HEV.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Dexamethason, powder, BioReagent, suitable for cell culture, ≥97%
Sigma-Aldrich
Dexamethason, ≥98% (HPLC), powder
Sigma-Aldrich
Kalium, chunks (in mineral oil), 98% trace metals basis
USP
Tacrolimus, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Prednisolon, ≥99%
Sigma-Aldrich
Kaliumhydrid, 30 wt % dispersion in mineral oil
Sigma-Aldrich
Dexamethason, powder, γ-irradiated, BioXtra, suitable for cell culture, ≥80% (HPLC)
USP
Dexamethason, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
FK-506 Monohydrat, ≥98% (HPLC)
USP
Prednisolon, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Kaliumhydrid, in paraffin
Sigma-Aldrich
Dexamethason, meets USP testing specifications
Supelco
Dexamethason, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Prednisolon, Pharmaceutical Secondary Standard; Certified Reference Material
Prednisolon, European Pharmacopoeia (EP) Reference Standard
Supelco
Prednisolon, VETRANAL®, analytical standard
Sigma-Aldrich
Dexamethason, tested according to Ph. Eur.
Supelco
Dexamethason, VETRANAL®, analytical standard
Dexamethason, European Pharmacopoeia (EP) Reference Standard
Dexamethason, British Pharmacopoeia (BP) Assay Standard
Dexamethason für die Systemeignung, European Pharmacopoeia (EP) Reference Standard
Dexamethason für die Peakidentifizierung, European Pharmacopoeia (EP) Reference Standard
Prednisolon, British Pharmacopoeia (BP) Assay Standard
Prednisolon für die Systemeignung, European Pharmacopoeia (EP) Reference Standard
Prednisolon für die Peakidentifizierung, European Pharmacopoeia (EP) Reference Standard